Panelists provide their perspective on the appropriate settings in which to use Zerbaxa (ceftolozane) or Avycaz (ceftazidime/avibactam) for Pseudomonas infections and reflect on which dosing methods are the safest.
Panelists discuss their personal approaches to treating Pseudomonas infections when an earlier strategy has failed, taking into consideration past treatments, a patient’s sepsis status, and timely decision making.
Panelists discuss the prevalence of acute bacterial skin and skin structure infections, including MRSA, in the community, as well as risk factors, susceptibility, and increased resistance to oral antibiotics such as Keflex.
Peter L. Salgo, MD; Yoav Golan, MD; and Bruce M. Jones, PharmD, BCPS, identify the commonalities of ABSSSI, including the predominant pathogens, such as Staphylococcus aureus and Streptococcus, and gram-positive infections.
Panelists reflect on their personal upfront approaches to treating Pseudomonas infections before lab results return, considering monotherapy versus treatment cocktails and the inherent risks that need to be accounted for.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512